A year after orchestrating Sucampo Pharma’s sale to Mallinckrodt, Peter Greenleaf is still in hot demand. Aurinia has poached him from the helm of Cerecor, where he’s helped lay a foundation for a new pipeline for orphan neurological disorders in the past year.
Prezista (darunavir) : Janssen Sc. Ireland vs. Amneal Pharma
With its plan for a spinoff into two companies, Mallinckrodt will create an API and generics operation with a large controlled substances and acetaminophen business and seven manufacturing facilities split between the U.S. and Japan.
Prolensa (Bromfenac) : Senju Pharmaceutical, Bausch & Lomb Pharma vs. Amneal Pharmaceuticals
Reuters) - Mallinckrodt Plc (MNK.N) plans to spin off its specialty generics business to shareholders by the second half of 2019, but said it was still open to a sale of the unit.
AMITIZA® (lubiprostone) : Sucampo Pharmaceuticals vs. Sun Pharmaceutical
Synergy's been trying to sell itself for more than three years, but no buyer's willing to pay enough, the company admitted Thursday. Even worse? With its Trulance launch on the skids, Synergy's running out of money. If it can’t renegotiate terms with its lender, bankruptcy could be next.
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced it has closed the acquisition of Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, including its commercial and development assets.
Mallinckrodt is trying to reduce its reliance on cash cow product Acthar (corticotropin) for infantile spasms and multiple sclerosis, which brought in sales of almost $309m in the third quarter of 2017, down 6%. Acthar’s slowdown has been attributed by the company to payer resistance affecting prescription fulfilment, and the drug has also been in the spotlight in the US over price increases that culminated in a payer lawsuit a few weeks ago.
Suffering from a rep based more on exploiting markets than developing new drugs, Mallinckrodt $MNK is beefing up its pipeline of rare disease drugs with the $1.2 billion buyout of Sucampo $SCMP. The deal delivers one marketed drug — Amitiza (lubiprostone) for constipation — as well as two experimental ones, both in late-stage development.